Full Press Release Details
SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday, November 12, 2025, to review third quarter 2025 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via thisweblink.
A replay of the webcast and earnings news release will be available through theInvestor Relationssection of Legend Biotech’s website under theEvents and Presentationssection approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
With over 2,800 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more atwww.legendbiotech.com, and follow us onLinkedIn.